Navigation Links
deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer
Date:12/15/2010

Reykjavik, ICELAND, 15 December 2010 Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome (SNPs) that impact individual baseline levels of prostate specific antigen, or PSA. Testing for PSA levels is the most commonly used screening tool for the detection of prostate cancer. A prostate biopsy is routinely recommended for men with PSA above a certain threshold. However, PSA levels can rise for reasons unrelated to prostate cancer and baseline healthy levels vary substantially between individuals, resulting in many men without cancer being biopsied while cancer in others is not detected. The paper published today demonstrates that analysis of four SNPs can be used to derive a personalized PSA threshold that more accurately identifies those men who are more likely to have a positive biopsy and for whom one should therefore be recommended.

"This is straighforward genetics with direct clinical utility. Detected early, prostate cancer can be treated with near total success. The challenge is to more effectively risk stratify the population, identifying and biopsying those at high risk and with aggressive disease while minimizing the number of negative biopsies we perform. And using the genetics we are improving the sensitivity and specificity of PSA testing. Like virtually every protein in the body, PSA levels vary between individuals according to SNPs that regulate gene expression. The SNPs reported today enable us to personalize PSA thresholds, thereby changing the recommendation on whether to biopsy for a substantial proportion of men. Moreover, the discriminatory power of testing for these SNPs is highest when done in tandem with the SNPs associated directly with risk of the disease measured by our deCODE ProstateCancer test. We are working to swiftly incorporate these PSA markers into our testing portfolio," said Kari Stefansson, CEO of deCODE and senior author on the study.

The paper, entitled "Genetic correction of PSA values using sequence variants associated with PSA levels," is published today online in Science Translational Medicine at www.ScienceTranslationalMedicine.org and will appear in an upcoming print edition of the journal. The study was conducted in several stages and involved tens of thousands of men with and without prostate cancer. First, more than 300,000 SNPs were analyzed in 16,000 Icelandic men with PSA measurements but who had never been diagnosed with prostate cancer. SNPs that correlated with PSA levels were identified and then validated in a cohort from the UK. These SNPs were then studied in large case-control cohorts from Iceland, the Netherlands, Spain, Romania and the US to establish the association with PSA levels independent of risk of prostate cancer itself. The authors then demonstrated how measuring four SNPs correlated with PSA levels can be used to obtain a personalized threshold for when to biopsy, and that using such thresholds improves the ratio of positive to negative biopsies. The greatest improvement in prediction accuracy was seen when men are tested both for the PSA correction SNPs as well as a panel of prostate cancer risk SNPs detected by the deCODE ProstateCancer test.


'/>"/>

Contact: Edward Farmer
edward.farmer@decode.is
354-863-1923
deCODE genetics
Source:Eurekalert

Related medicine news :

1. Scientists decode secrets of a very common virus that can cause cancer
2. Physicists use graphene to decode DNA
3. The language of RNA decoded: Study reveals new function for pseudogenes and noncoding RNAs
4. UT professor defines play, discovers even turtles need recess
5. Research discovers how the deaf have super vision
6. Colorado researcher discovers mechanism for changing adult cells into stem-like cells
7. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
8. TGen-Mayo Clinic study discovers role of DNA methylation in multiple myeloma blood cancer
9. Virginia Tech professor discovers new TB pathogen
10. UCSF-led team discovers familial link in rare childhood leukemia
11. UR discovers new way to boost vaccines, seeks patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Dental Center, is currently offering complimentary consultations and financing for orthodontics for a ... for bite irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and ...
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... ... 16, 2017 , ... Atlanta-based incentive company Incentive Solutions ... wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide BraunAbility a debit ... With this new incentive plan, BraunAbility plans to continue their tradition of excelling ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water ... Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power of ...
(Date:1/16/2017)... ... 2017 , ... In 1985, the International Association of Eating ... an international multidisciplinary group of healthcare treatment providers and helping professions who treat ... mission at the grassroots level, iaedp launched MemberSHARE, an online peer community solely ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)...  This report by Persistence Market Research examines ... the period 2016–2024. The primary objective of the ... to market opportunities in the global peripherally inserted ... the various dynamics that are expected to influence ... global peripherally inserted central catheters market over the ...
(Date:1/16/2017)... 16, 2017 Derek H. Potts , ... was recently appointed Liaison Counsel in California,s ... Xarelto cases. In this role, Potts was assigned to ... actively assist the Court and Co Lead Plaintiff,s Counsel. ... Adelman Jackson Fairchild & Wade and Ruth ...
(Date:1/16/2017)... ROCKVILLE, Md. , Jan. 16, 2017 /PRNewswire/ ... tomography (CT) systems market is valued at $4.9 ... applications for CT, coupled with an aging population ... incidence of chronic disease, is propelling the market ... report, Computed Tomography Markets , focuses on ...
Breaking Medicine Technology: